Immune checkpoint inhibitors (i.e. ICI) represent a new Nobel-Prize worth immunotherapy with immense success in some incurable cancers, which target s inhibitory costimulatory molecules on the surface of T cells (like PD-1 or CTLA-4). The gene discussed is PDCD1; the disease is cancer.